key: cord-0957398-j5r9hlrc
authors: Piñar-Gutiérrez, Ana; Remón-Ruiz, Pablo; Soto-Moreno, Alfonso
title: CASE REPORT: Pituitary apoplexy after COVID-19 vaccination
date: 2021-11-13
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.09.028
sha: 8f1aafc2d854e3ec652f1cf27929cf119103bf95
doc_id: 957398
cord_uid: j5r9hlrc

nan

The discovery and widespread use of different SARS-CoV-2 vaccines has made it possible to combat the COVID-19 disease in an effective and safe way. Among the adverse effects that have been observed during the implementation of the vaccination campaign is the appearance of thrombosis and bleedings associated with a syndrome known as Vaccine-Induced Thrombotic Thrombocytopenia (VITT), related only to viral vector vaccines. VITT is more frequent in young women and appears to be a phenomenon similar to heparin-induced thrombocytopenia and have an autoimmune source 1,2 .

Pituitary apoplexy, described as an infarction or hemorrhage of the pituitary gland, is a rare entity generally associated with pituitary adenomas and constitutes, in most cases, an endocrine emergency that may require decompressive surgery and specific treatment.

Currently, in the context of SARS-CoV-2 infection, rare and specific cases of pituitary apoplexy have been described both associated and not associated with pituitary adenomas. However, to date, there have been no reported cases of vaccine-associated pituitary apoplexy 3 .

We present the case of a 37-year-old woman who, 5 days after vaccination with ChAdOx1-S, developed a high-intensity frontal headache with partial relief with habitual analgesia. A complete physical examination was performed, which did not demonstrate the presence of neurological focality, cranial nerve involvement, or campimetric involvement. Despite this, due to the intensity of the headache, a brain 

Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to

Natural SARS-CoV-2 Infection

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

COVID-19 and the pituitary

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use

The authors declare no conflict of interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.